New hope for Drug-Resistant lung cancer: Fourth-Generation pill enters human trials
NCT ID NCT06461156
First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 30 times
Summary
This study tests a new oral drug, HS-10504, for people with advanced non-small cell lung cancer that has stopped responding to other targeted therapies. The drug is designed to attack a specific genetic change (C797S mutation) in cancer cells. The main goals are to find the safest dose and check for side effects in about 230 participants.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED OR METASTATIC NSCLC are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The First Affiliated Hospital of Guangzhou Medical University
RECRUITINGGuangzhou, China
Conditions
Explore the condition pages connected to this study.